The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease

By Cremieux Pierre-Yves   Van Audenrode Marc   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2329-2336

Informa Healthcare

Access to resources Recommend Favorite

Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa

By Hymes Jeffrey   Bickimer Tammy   Jackson James H.   Bookhart Brahim K.   Mody Samir H.   Tak Piech Catherine  

Current Medical Research and Opinion, Vol. 23, Iss. 8, 2007-08 ,pp. : 1931-1937

Informa Healthcare

Access to resources Recommend Favorite

Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease

By Einarson Thomas   Machado Marcio   Walker John   Iskedjian Michael   Cremieux Pierre-Yves   Van Audenrode Marc   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1571-1574

Informa Healthcare

Access to resources Recommend Favorite

Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa

By Pannier Anne   Jordan Paul   Dougherty Frank C.   Bour Fabrice   Reigner Bruno  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3025-3032

Informa Healthcare

Access to resources Recommend Favorite

Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity‐matched analysis

By  

NEPHROLOGY, Vol. 20, Iss. S4, 2015-12 ,pp. : 22-28

John Wiley & Sons Inc

Access to resources Recommend Favorite